This finding may argue for re-evaluation of short-acting analogs and give cause to further consider approaches [62] to reverse loss of secretory response in patients with type 2 diabetes following long-term SU treatment, and thereby prolong the use of pharmacotherapies and delay the need to switch to insulin. This evidence concerns the gene INS and type 2 diabetes mellitus.